Wellspan radiation oncology

Share on social media About the Business WellSpan Radiation Oncology - York Cancer Center offers you radiation therapy services in York, Pennsylvania, United States. Contacts Location Working hours Monday: 7 AM to 5 PMTuesday: 7 AM to 5 PMWednesday: 7 AM to 5 PMThursday: 7 AM to 5 PMFriday: 7 AM to 5 PMSaturday: ClosedSunday: Closed Amenities & Services Information last updated: November 19, 2024 Reviews on WellSpan Radiation Oncology - York Cancer Center OnMend moderators take care of reviews trustiness. Each review submission is followed by check if it's real and worthy to publish. All reviews submitted on this website are handled with strict privacy and are not shared with AI providers or used in any form of AI learning or training. Start your review of WellSpan Radiation Oncology - York Cancer Center. Overall rating of WellSpan Radiation Oncology - York Cancer Center on OnMend N/A stars (no reviews) Frequently Asked Questions about WellSpan Radiation Oncology - York Cancer Center Where is the WellSpan Radiation Oncology - York Cancer Center situated at? WellSpan Radiation Oncology - York Cancer Center is situated at 25 Monument Rd, York, Pennsylvania, United States. What days are WellSpan Radiation Oncology - York Cancer Center open? Friday, Thursday, Wednesday, Tuesday, Monday. Found incorrect information? Featured radiation therapy nearby:

Home Doctors Pennsylvania York Sherif Yacoub Doctors in York PA MEDICARE Radiation Oncology specialist in York PA Dr. Sherif Yacoub is a Radiation Oncology Specialist in York, Pennsylvania. He graduated with honors in 1985. Having more than 40 years of diverse experiences, especially in RADIATION ONCOLOGY, Dr. Sherif Yacoub affiliates with many hospitals including Wellspan York Hospital, Gettysburg Hospital, cooperates with many other doctors and specialists in medical group Wellspan Medical Group. Call Dr. Sherif Yacoub on phone number (717) 741-8180 for more information and advice or to book an appointment. Basics Full Name Sherif Yacoub Gender Male PECOS ID 7911899414 Experience 40+ years of diverse experiences Sole Proprietor No - He does not own any un-incorporated business by himself. Accepts Medicare Assignment He does accept the payment amount Medicare approves and not to bill you for more than the Medicare deductible and coinsurance. Medical Specialities RADIATION ONCOLOGY Credentials Doctor of Medicine (MD) Education & Training Dr. Sherif Yacoub attended to a university and then graduated in 1985 NPPES Information NPI #: 1821099912 Enumeration Date: Aug 10th, 2005 Last Update Date: Sep 16th, 2020 Request for update Dr. Sherif Yacoub has primarily specialised in Radiation Oncology for over 40 years. SpecializationLicense NumberIssued State Radiology / Radiation Oncology 35078539 Ohio Radiology / Radiation Oncology MD432984 Pennsylvania Hospital Name Hospital Type Hospital Ownership Location Wellspan York Hospital Acute Care Hospitals Voluntary non-profit - Private York, Pennsylvania Gettysburg Hospital Acute Care Hospitals Voluntary non-profit - Private Gettysburg, Pennsylvania OrganizationNumber of Members Wellspan Medical

Advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90–03. Head Neck. 2006;28:287–96.Article PubMed Google Scholar Download referencesAcknowledgementsWe would like to thank the Swiss State Secretariat for Education, Research and Innovation (SERI) for supporting this trial.Author informationAuthors and AffiliationsDepartment of Radiation Oncology, Charité Universitätsmedizin Berlin, Berlin, GermanyPirus Ghadjar, David Kaul, Harun Badakhshi & Volker BudachSAKK Coordinating Center, Bern, SwitzerlandStefanie HayozDepartment of Radiation Oncology, University Hospital Basel, Basel, SwitzerlandFrank ZimmermannDepartment of Radiation Oncology, Kantonsspital Aarau, Aarau, SwitzerlandStephan BodisDepartment of Radiation Oncology, Clinique de Genolier, Genolier, SwitzerlandJacques BernierDepartment of Radiation Oncology, University Hospital Zürich, Zürich, SwitzerlandGabriela StuderDepartment of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, SwitzerlandLudwig PlasswilmDepartment of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, SwitzerlandDaniel M AebersoldAuthorsPirus GhadjarYou can also search for this author in PubMed Google ScholarStefanie HayozYou can also search for this author in PubMed Google ScholarFrank ZimmermannYou can also search for this author in PubMed Google ScholarStephan BodisYou can also search for this author in PubMed Google ScholarDavid KaulYou can also search for this author in PubMed Google ScholarHarun BadakhshiYou can also search for this author in PubMed Google ScholarJacques BernierYou can also search for this author in PubMed Google ScholarGabriela StuderYou can also search for this author in PubMed Google ScholarLudwig PlasswilmYou can also search for this author in PubMed Google ScholarVolker BudachYou can also search for this author in PubMed Google ScholarDaniel M AebersoldYou can also search for this author in PubMed Google ScholarConsortiaFor the Swiss Group for Clinical Cancer Research (SAKK)Corresponding authorCorrespondence to Pirus Ghadjar.Additional informationCompeting interestsThe authors declare that they have no competing interests.Authors’ contributionsEach author had participated sufficiently in the work to take public responsibility for appropriate portions of the content. PG, SH and DMA designed this secondary analysis. SH and PG performed the statistical analysis. All authors helped to interpret the data. The manuscript was written by PG and SH, all other authors helped and finally approved the final manuscript.Rights and permissions This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( which

Short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 30(31):3827–33Article PubMed Google Scholar Bisschop C, van Dijk TH, Beukema JC et al (2017) Short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical treatment in primary stage IV rectal cancer: long-term results of a phase II study. Ann Surg Oncol 24(9):2632–8Article CAS PubMed PubMed Central Google Scholar Jin J, Tang Y, Hu C et al. (2022) Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol 0(0):JCO.21.01667Bascoul-Mollevi C, Gourgou S, Borg C et al (2023) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): health-related quality of life longitudinal analysis. Eur J Cancer 186:151–165Article CAS PubMed Google Scholar O'Brien TN, Shahrokni A, Horgan AM (2023) Total neoadjuvant therapy for rectal cancer: totally not translatable to the older patient? J Geriatr Oncol 14(1):101348Article CAS PubMed Google Scholar Shi Q, Weiser MR, Gollub MJ et al (2023) PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048). J Clin Oncol 41(17_suppl):LBA2–LBAArticle Google Scholar Download referencesFundingThis research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.Author informationAuthors and AffiliationsPatrick G Johnston Centre for Cancer Research, Queen’s University, Belfast, Northern IrelandTimothy O’BrienDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, NetherlandsGeke HospersMedical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-Lès-Nancy, Nancy, FranceThierry ConroyUniversité de Lorraine, APEMAC, Équipe MICS, Nancy, FranceThierry ConroyDivision of Medical Oncology, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USAHeinz-Josef LenzDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering, New York, NY, USAJesse Joshua SmithDepartment of Surgery, Cork University Hospital, University College Cork, Cork, IrelandEmmet AndrewsDepartment of Radiation Oncology, St Luke’s Radiation Oncology Network, Dublin, IrelandBrian O’NeillDepartment of Medical Oncology, University Hospital Galway, Newcastle